重新定义肿瘤学 I 期试验的主要目标。 - Suppr

Suppr

超能文献

Redefining the primary objective of phase I oncology trials.

作者信息

Ratain Mark J

出版信息

Nat Rev Clin Oncol. 2015 Mar;12(3):126. doi: 10.1038/nrclinonc.2014.157. Epub 2014 Sep 9.

DOI:10.1038/nrclinonc.2014.157

PMID:25200413

Abstract

摘要

相似文献

Redefining the primary objective of phase I oncology trials.

Nat Rev Clin Oncol. 2015 Mar;12(3):126. doi: 10.1038/nrclinonc.2014.157. Epub 2014 Sep 9.

Targeted therapies: redefining the primary objective of phase I oncology trials.

Nat Rev Clin Oncol. 2014 Sep;11(9):503-4. doi: 10.1038/nrclinonc.2014.135. Epub 2014 Aug 5.

Redefining the primary nurse role in oncology care: A 21st century perspective.

Can Oncol Nurs J. 2006 Summer;16(2):99-109. doi: 10.5737/1181912x16299103.

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.

Annu Rev Med. 2018 Jan 29;69:319-331. doi: 10.1146/annurev-med-062016-050343. Epub 2017 Nov 9.

A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.

Oncologist. 2020 Jun;25(6):532-540. doi: 10.1634/theoncologist.2019-0615. Epub 2020 Jan 14.

Redefining perspectives, processes, and performance in oncology services for the year 2000.

J Oncol Manag. 1997 Mar-Apr;6(2):11-8.

Formal statistical testing and inference in randomized phase II trials in medical oncology.

Am J Clin Oncol. 2013 Apr;36(2):143-5. doi: 10.1097/COC.0b013e3182436e6c.

Communication about the risks and benefits of phase I pediatric oncology trials.

Contemp Clin Trials. 2015 Mar;41:139-45. doi: 10.1016/j.cct.2015.01.015. Epub 2015 Jan 29.

[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB].

Bull Cancer. 2015 Jan;102(1):73-82. doi: 10.1016/j.bulcan.2014.10.001. Epub 2015 Jan 2.

Redefining the Treatment Endpoints in Oncology.

Oncologist. 2021 Mar;26(3):e521. doi: 10.1002/onco.13688. Epub 2021 Feb 12.

引用本文的文献

Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.

J R Stat Soc Ser C Appl Stat. 2017 Nov;66(5):1015-1030. doi: 10.1111/rssc.12195. Epub 2016 Nov 7.

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.

Clin Cancer Res. 2016 Feb 1;22(3):553-9. doi: 10.1158/1078-0432.CCR-15-0339. Epub 2015 Aug 31.

本文引用的文献

Targeted therapies: redefining the primary objective of phase I oncology trials.

Nat Rev Clin Oncol. 2014 Sep;11(9):503-4. doi: 10.1038/nrclinonc.2014.135. Epub 2014 Aug 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Redefining the primary objective of phase I oncology trials.

Nat Rev Clin Oncol. 2015 Mar;12(3):126. doi: 10.1038/nrclinonc.2014.157. Epub 2014 Sep 9.

Targeted therapies: redefining the primary objective of phase I oncology trials.

Nat Rev Clin Oncol. 2014 Sep;11(9):503-4. doi: 10.1038/nrclinonc.2014.135. Epub 2014 Aug 5.

Redefining the primary nurse role in oncology care: A 21st century perspective.

Can Oncol Nurs J. 2006 Summer;16(2):99-109. doi: 10.5737/1181912x16299103.

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.

Annu Rev Med. 2018 Jan 29;69:319-331. doi: 10.1146/annurev-med-062016-050343. Epub 2017 Nov 9.

A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.

Oncologist. 2020 Jun;25(6):532-540. doi: 10.1634/theoncologist.2019-0615. Epub 2020 Jan 14.

Redefining perspectives, processes, and performance in oncology services for the year 2000.

J Oncol Manag. 1997 Mar-Apr;6(2):11-8.

Formal statistical testing and inference in randomized phase II trials in medical oncology.

Am J Clin Oncol. 2013 Apr;36(2):143-5. doi: 10.1097/COC.0b013e3182436e6c.

Communication about the risks and benefits of phase I pediatric oncology trials.

Contemp Clin Trials. 2015 Mar;41:139-45. doi: 10.1016/j.cct.2015.01.015. Epub 2015 Jan 29.

[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB].

Bull Cancer. 2015 Jan;102(1):73-82. doi: 10.1016/j.bulcan.2014.10.001. Epub 2015 Jan 2.

Redefining the Treatment Endpoints in Oncology.

Oncologist. 2021 Mar;26(3):e521. doi: 10.1002/onco.13688. Epub 2021 Feb 12.

引用本文的文献

Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.

J R Stat Soc Ser C Appl Stat. 2017 Nov;66(5):1015-1030. doi: 10.1111/rssc.12195. Epub 2016 Nov 7.

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.

Clin Cancer Res. 2016 Feb 1;22(3):553-9. doi: 10.1158/1078-0432.CCR-15-0339. Epub 2015 Aug 31.

本文引用的文献

Targeted therapies: redefining the primary objective of phase I oncology trials.

Nat Rev Clin Oncol. 2014 Sep;11(9):503-4. doi: 10.1038/nrclinonc.2014.135. Epub 2014 Aug 5.